Abstract:TNF induces bone loss in common bone diseases by promoting osteoclast formation directly and indirectly, but it also limits osteoclast formation by inducing expression of NF-κB p100. Osteoclast precursors (OCPs) are derived from M1 (inflammatory) and M2 (resident) macrophages. However, it is not known if TNF stimulates or limits osteoclast formation through regulation of M1 or M2 differentiation or if RelB, a partner of p100, is involved. To investigate these questions, we treated bone marrow cells (BMCs) with M-CSF alone or in combination with TNF to enrich for OCPs, which we called M-OCPs and T-OCPs, respectively. We found that TNF switched CD11b+F4/80+ M-OCPs from Ly6C-Gr1- M2 to Ly6C+Gr1-CD11c+ and Ly6C-Gr1-CD11c+ M1 cells. RANKL induced osteoclast formation from both Ly6C+Gr1- and Ly6C-Gr1- T-OCPs, but only from Ly6C+Gr1- M-OCPs, which formed significantly fewer osteoclasts than T-OCPs. Importantly, Ly6C+Gr1- cells from both M- and T-OCPs have increased expression of the M1 marker genes, iNOS, TNF, IL-1β and TGFβ1, compared to Ly6C-Gr1- cells, and Ly6C-Gr1- cells from T-OCPs also have increased expression of iNOS and TGFβ1 compared to cells from M-OCPs. Both RANKL and TNF increased RelB mRNA expression. TNF significantly increased RelB protein levels, but RANKL did not because it also induced RelB proteasomal degradation. TNF inhibited RANKL-induced NFATc1 mRNA expression and osteoclast formation from M-OCPs, but not from T-OCPs, and it did not induce Ly6C+Gr1-CD11c+ or Ly6C-Gr1-CD11c+ M1 macrophages from RelB-/- BMCs. Furthermore, overexpression of RelB in M-OCPs reduced RANKL-induced osteoclast formation and NFATc1 mRNA expression, but it increased TNF-induced OC formation without affecting NFATc1 levels. Thus, TNF induction of RelB directly mediates terminal osteoclast differentiation independent of NFATc1 and limits RANKL-induced osteoclastogenesis by inhibiting NFATc1 activation. However, the dominant role of TNF is to expand the OCP pool by switching the differentiation of M-CSF-induced M2 to M1 macrophages with enhanced osteoclast forming potential. Strategies to degrade RelB could prevent TNF-induced M2/M1 switching and reduce osteoclast formation.

14-3-3ζ suppresses RANKL signaling by destabilizing TRAF6

TRAF family member-associated NF-κB activator (TANK) induced by RANKL negatively regulates osteoclasts survival and function.

BCL3 Regulates RANKL-induced Osteoclastogenesis by Interacting with TRAF6 in Bone Marrow-Derived Macrophages.

RANKL Downregulates Cell Surface CXCR6 Expression Through JAK2/STAT3 Signaling Pathway During Osteoclastogenesis

RhoA Promotes Osteoclastogenesis and Regulates Bone Remodeling Through Mtor-Nfatc1 Signaling.

STAT3 Restrains RANK- and TLR4-mediated Signalling by Suppressing Expression of the E2 Ubiquitin-Conjugating Enzyme Ubc13

Crosstalk Between STAT3 and RANK Signaling Pathways During Osteoclastogenesis (174.7)

RANKL Signaling in Bone Marrow Mesenchymal Stem Cells Negatively Regulates Osteoblastic Bone Formation

YTHDF2 Mediates LPS-induced Osteoclastogenesis and Inflammatory Response Via the NF-κB and MAPK Signaling Pathways

Nrf2 Mitigates RANKL and M-CSF Induced Osteoclast Differentiation via ROS-Dependent Mechanisms

TNF Induction of NF-κB RelB Enhances RANKL-Induced Osteoclastogenesis by Promoting Inflammatory Macrophage Differentiation but also Limits It through Suppression of NFATc1 Expression

STAT3 controls osteoclast differentiation and bone homeostasis by regulating NFATc1 transcription

Specific RANK Cytoplasmic Motifs Drive Osteoclastogenesis.

Decidual Γδt Cells Educated by CXCL16 Promotes Growth of JEG-3 Cells

Inhibition of Osteoclastogenesis by RNA Interference Targeting RANK

Correlating Rank Ligand/Rank Binding Kinetics with Osteoclast Formation and Function

Mutations within the TNF-Like Core Domain of RANKL Impair Osteoclast Differentiation and Activation

Inhibition of NFAM1 suppresses phospho-SAPK/JNK signaling during osteoclast differentiation and bone resorption

[Osteoclast Differentiation Regulated by Receptor Activator of Nuclear Factor Kappab Probably Through a Novel Signaling Pathway].

Annexin A3 Accelerates Osteoclast Differentiation by Promoting the Level of RANK and TRAF6

Calcium Channel TRPV6 is a Novel Regulator in RANKL-induced Osteoclastic Differentiation and Activity through the IGF–PI3K–AKT Pathway